D.C. Circuit Court Affirms FDA Misclassified Contrast Agent As A Drug
WASHINGTON, D.C. — The District of Columbia Circuit U.S. Court of Appeals on April 16 said the Food and Drug Administration erred when it classified a contrast agent as a drug...To view the full article, register now.
Already a subscriber? Click here to view full article